Progress of propylene glycol-free melphalan hydrochloride for injection in hematologic malignancies
10.3760/cma.j.cn115356-20231113-00071
- VernacularTitle:无丙二醇的注射用盐酸美法仑在血液肿瘤中的研究进展
- Author:
Xiaoyu ZHANG
1
;
Erlie JIANG
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Hematologic neoplasms;
Melphalan;
Drug therapy, combination;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2025;34(1):54-57
- CountryChina
- Language:Chinese
-
Abstract:
Mephalan is a classic nitrogen mustard alkylating agent, and its intravenous formulation is used in the treatment of various hematologic malignancies. In 2018, propylene glycol-free melphalan hydrochloride for injection (PGF-Mel) which uses a novel cyclodextrin encapsulation technology was approved for marketing in China, and it has better solubility and stability after reconstitution than propylene glycol-solubilized melphalan (e.g., Alkeran injection). This article reviews the basic pharmacological properties, systemic drug exposure and efficacy and safety of PGF-Mel in different hematologic malignancies.
